Iacobelli S, Arno E, Sismondi P, Natoli C, Gentiloni N, Scambia G, Giai M, Cortese P, Panici P B, Mancuso S
Cattedra di Oncologia Clinica, Università G. D'Annunzio, Chieti, Italy.
Breast Cancer Res Treat. 1988 Apr;11(1):19-30. doi: 10.1007/BF01807554.
An enzyme-linked immuno-absorbent assay has been developed for the detection of a circulating tumor-associated antigen, 90K, recognized by murine monoclonal antibody SP-2 (Iacobelli et al., Cancer Res 46: 3005-3010, 1986). This assay was found to be simple and reproducible. Using this method, 6% of 165 apparently healthy individuals and 15% of 91 patients with benign breast disease showed 90K levels above 1.7 units/ml. Approximately 50% of 129 patients with advanced breast cancer demonstrated serum antigen levels above 1.7 units/ml. All histological types of breast cancer were positive, and no association between the incidence of elevated 90K levels and other prognostic variables could be detected. The titers of 90K were significantly higher in sera from advanced-stage (3 and 4) patients than in those from patients with limited-stage (1 and 2) disease. Elevated 90K levels were also observed in patients with carcinomas of other sites, including gastrointestinal, gynecological, and lung tumors. By means of the immune blotting technique, the antigenic components carrying the determinants in serum and extracts of breast cancer cells have been identified. The levels of 90K did not correlate with those of CA 15-3 or CEA. The measurement of 90K in sera appears to be a useful adjunct to other available assays for the detection and monitoring of breast cancer and other malignant tumors.
已开发出一种酶联免疫吸附测定法,用于检测一种循环肿瘤相关抗原90K,该抗原可被鼠单克隆抗体SP-2识别(Iacobelli等人,《癌症研究》46: 3005 - 3010,1986)。发现该测定法简单且可重复。使用这种方法,165名明显健康的个体中有6%以及91名良性乳腺疾病患者中有15%的90K水平高于1.7单位/毫升。129名晚期乳腺癌患者中约50%的血清抗原水平高于1.7单位/毫升。所有组织学类型的乳腺癌均呈阳性,且未检测到90K水平升高的发生率与其他预后变量之间存在关联。晚期(3期和4期)患者血清中90K的滴度显著高于局限期(1期和2期)疾病患者。在其他部位的癌症患者中也观察到90K水平升高,包括胃肠道、妇科和肺部肿瘤。通过免疫印迹技术,已鉴定出乳腺癌细胞血清和提取物中携带决定簇的抗原成分。90K的水平与CA 15 - 3或CEA的水平无关。血清中90K的测定似乎是检测和监测乳腺癌及其他恶性肿瘤的其他现有测定法的有用辅助手段。